Featured Research Partner
OCRI is partnering with the NFL Former Players - Charlotte Chapter NFLPACLT to present the 2nd Annual I-PASS Charity event on 3.29.14
FDA Clinical TrialsFDA Clinical Trials
Each year hundreds of patients are referred to medical clinics, such as OrthoCarolina, P.A., for state-of-the-art care and for participation in clinical trials. Clinical trials are designed to develop new devices, evaluate new medications, improve materials and systems, and improve surgical procedures. At the present time, the OrthoCarolina Research Institute is working with fourteen FDA-controlled clinical trials and two Humanitarian Device Exemption (HDE) studies that serve and support the public in providing state-of-the-art surgical treatments and techniques. Representative of these investigative trials are a total shoulder prosthesis design and instrumentation evaluation, a shoulder stability device study, an ankle fusion and ankle arthroplasty comparison, an assessment of design and materials for total joint replacements, and an evaluation of treatment options for diabetic foot infections.
All clinical trial proposals and studies are reviewed and approved by the OCRI Research Advisory Committee (RAC) and an Institutional Review Board (IRB) prior to implementation. Stringent protocols are required to ensure the safety of all participating individuals and to make certain that participating surgeons follow the same study procedures and guidelines.
Click here for a list of our current studies:
Studies Open to Enrollment:
Total Joint Replacement
Title: Multi-Center Trial of the Continuum™ Ceramic Bearing System in Total Hip Arthroplasty
Investigators: Drs. Thomas McCoy and Erin Hermann, PA-C
Objective: To evaluate the safety and efficacy of the Continuum™ Ceramic Bearing System in unilateral primary total hip arthroplasty.
Title: A prospective, comparative, randomized, single blind, multi-center study of the TrinityTM BIOLOX deltaTM Ceramic-on-Ceramic Total Hip Replacement System vs. TrinityTM Acetabular Hip System
Investigators: Drs. Masonis, Melvin, and Andrew Patterson PA-C
Objective: To demonstrate clinical non-inferiority of an investigational device, TrinityTM BIOLOX deltaTM Ceramic-on-Ceramic Total Hip System, with respect to a Composite Clinical Success criterion (CCS) at the Month 24 endpoint
Title: A Phase II randomized, single ascending dose, double-blinded, placebo controlled, multi-center study of the effects of rhPDGF-BB Injection on lateral Epicondylitis
Investigators: Drs. Perlik, Gantt, Osier, Baker, Ward, Chadderdon, Gaston, Lewis, Gaul, Boatright, and Hamid
Objective: To evaluate the effectiveness of rhPDGF-BB Injection, as a treatment for lateral epicondylitis
Title: SMART- Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain
“A prospective randomized, double-blind, controlled investigation evaluating the Intracept Intraosseous Nerve Ablation System for the reduction of pain in patients with chronic axial low back pain “
Sponsor: Relievant Medisystems
Investigators: Drs. Al Rhyne, Sam Bhagia, and Monica Overbaugh, PA-C
Objective: To evaluate the safety and effectiveness of RF ablation using the Intracept Intraosseous Nerve Ablation System to ablate intraosseous nerves for the relief of chronic axial low back pain.
Title: “VEPTR Implantation to Treat Children with Early Onset Scoliosis without Rib Abnormalities: A Prospective Multicenter Study”
Sponsor: Chest Wall and Spine Deformity Study Group
Investigator: J. Michael Wattenbarger, MD
Objective: To evaluate the use of unilateral or bilateral VEPTR devices, with or without expansion thoracoplasty, for preventing further progression of the Cobb angle, allowing for spinal growth and improving pulmonary function in the treatment of children with progressive scoliosis without rib abnormalities.
Title: Post-Market, Longitudinal Data Collection Study of DeNovo® NT for Articular Cartilage Defects of the Knee CSU2010-22B
Investigators: Drs. James Fleischli, Dana Piasecki, and Aaron Hewitt, PA-C
Objective: The purpose of this post-market study, is to collect additional long-term outcomes for DeNovo® NT treatment of articular cartilage lesion(s) of the knee in a standard clinical setting. Outcomes to be assessed include pain, function, activity levels and healthcare resource use. This is a post-market, multicenter, cohort study of the commercially-available DeNovo® NT graft.
Studies Closed to Enrollment (Long-term follow-up):
Total Joint Replacement
Title: A prospective, multicenter, non-randomized, clinical outcomes study of the R3® Acetabular System in patients with degenerative hip disease
Sponsor: Smith & Nephew
Investigator: John L. Masonis, MD
Objective: To determine the long-term safety and effectiveness of the R3 Acetabular System.
Title: A Prospective, Multi-Centered Study of the Birmingham Hip Resurfacing System
Sponsor: Smith & Nephew
Investigator: John Masonis, MD
Objective: To evaluate the longer-term safety and effectiveness of the BHR system.
Title: Prospective Multicenter Post Approval Study of the LPS-Flex Mobile Bearing Knee (Protocol#: 07-100)
Sponsor: Zimmer, Inc.
Investigators: Drs. Water Beaver and Thomas McCoy
Objective: The objective of Post Approval Study (PAS) is to assess the long-term performance of the NexGen® LPS-Flex Mobile Bearing Knee in the treatment of patients with severe knee pain or degenerative knee disease.
Title: PMA Post-Approval Study - CoMplete™ Acetabular Hip System (CoM)
Sponsor: DePuy/Johnson & Johnson
Investigators: Drs. Thomas Fehring, Bill Griffin, Bo Mason
Objective: Post Marktet Approval study on the CoMplete™ Acetabular Hip System (CoM). Only patients who previously participated in the IDE clinical trial are eligible for this study.
Title: RegenerexTM Tibial Tray Multi-Center Data Collection
Investigators: Dr. Suprock, Vanguard, and April Wrikstrom PA-C
Objective: To document the performance and clinical outcomes of the RegenerexTM Tibial Tray
Title: A Phase 3b Open-Label Historically-Controlled Study to Assess The Safety And Efficacy Of Two Concurrent Injections Of AA4500 In Adult Subjects With Multiple Dupuytren’s Contractures With Palpable Cords
Investigators: Drs. Perlik, Gantt, Osier, Baker, Ward, Chadderdon, Gaston, Lewis, Gaul, and Boatright
Objective: To assess the safety and efficacy of the simultaneous administration of two injections of AA4500 (Xiaflex) into the same hand with multiple Dupuytren’s contractures caused by palpable cords followed 24 to 72 hours later by a finger extension procedure.
Title: A Multicenter, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of PRODISC-C® to Anterior Cervical Discectomy and Fusion (ACDF) Surgery in the Treatment of Symptomatic Cervical Disc Disease (SCDD). [FDA-Device clinical trial] Sponsor: Synthes Spine
Investigators: Drs. Daniel Murrey, Al Rhyne, Bruce Darden, and Eric Laxer
Objective: To compare the safety and effectiveness of PRODISC-C® (investigational artificial disc implant) to ACDF surgery in the treatment of SCDD. The intent of PRODISC-C® is to treat degenerative disc disease by reducing the pain and neurological signs and symptoms, without fusing the vertebrae.
Title: The Investigational Plan for the Evaluation of the ACADIA™ Facet Replacement System (Pivotal IDE Trial) (Protocol #: 1020-9052)
Sponsor: Globus Medical
Investigators: Drs. Al Rhyne, Eric Laxer, Leo Spector, and Alden Milam
Objective: The purpose of this study is to evaluate the safety and effectiveness of the ACADIA Anatomic Facet Replacment System (AFRS) in patients with lateral, lateral recess and/or central canal stenosis due to facet degeneration at a single level from L3 to S1 who require a lumbar decompression and facetectomy compared to an instrumented posterolateral fusion control group. Safety of the AFRS device will be evaluated by the incidence, severity and device or procedure relatedness of all adverse events over the 24 month assessment period as compared to the control group. Effectiveness of the AFRS will be based on the improvement in symptom-related questionnaire scores, function, and neurological status.
Foot & Ankle
Title: A Prospective, Randomized, Controlled, Multi-Center, Pivotal Human Clinical Trial to Evaluate the Safety and Effectiveness of Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Sponsor: Biomimetic Therapeutics
Investigators: Drs. Robert Anderson, Bruce Cohen, W. Hodges Davis, Carroll Jones, and Greg Sanders, PA-C
Objective: To demonstrate equivalent clinical and radiologic outcomes as “gold
standard” (Autologous Bone Graft) in a representative clinical model
HUMANITARIAN DEVICE EXEMPTION (HDE) STUDIES (1)
A Humanitarian Use Device is a device used to diagnose or treat a disease or condition that affects fewer than 4,000 individuals in the United States per year and for which no similar device is available. The U.S. Food and Drug Administration (FDA) approves the use of Humanitarian Devices based primarily on evidence that it does not pose a significant risk of injury to the patient and that the potential benefit of the device to the health of the patient outweighs the risk of its use.
Title: HDE Application for Vertical Expandable Prosthetic Titaniium
Investigator: J. Michael Wattenbarger, MD
Objective: The Vertical Expandable Prosthetic Titanium Rib (VEPTR) is authorized by Federal law for use in the treatment of Thoracic Insufficiency Syndrome (TIS), the inability of the thorax to support normal respiration or lung growth, in skeletally immature patients. The effectiveness of this device for this use has not been demonstrated.